Stem Cell and Regenerative Therapies for Primary Ciliary Dyskinesia: Restoring Ciliary Function with iPSCDerived Airway Cells

Primary Ciliary Dyskinesia (PCD) is a genetic disorder that impairs ciliary function, leading to respiratory and fertility issues. While genetic mutations and stem cell-derived airway cells have been explored, effective regenerative therapies are still lacking. This study examines the potential of iPSCs in restoring ciliary function and advancing PCD treatments. Furthermore, it aims to evaluate the effectiveness of iPSC-derived airway cells in replicating functional cilia for potential regenerative therapies in PCD. Additionally, it seeks to identify genetic targets that may enhance treatment strategies. This study reviews existing literature to examine the role of stem cell-derived airway cells on restoring ciliary function in patients with PCD. Research from PubMed and Google Scholar was analyzed to conduct our literature review. Keywords such as “primary ciliary dyskinesia”, “stem cell”, and “regenerative therapy” utilizing Boolean operators. iPSCs derived from PCD patient cells were differentiated into airway epithelial cells. Functional assays revealed ciliary defects, such as reduced beat frequency and impaired mucociliary clearance. Gene-editing strategies partially restored ciliary function, and genetic profiling identified targets for potential therapies. This study highlights the potential of iPSC-derived airway cells in restoring ciliary function and advancing regenerative therapies for PCD. The findings support prior research on stem cell applications in respiratory diseases, validating iPSCs as a therapeutic option. Harnessing iPSC-derived airway cells marks significant progress in regenerative treatments for Primary Ciliary Dyskinesia. However, further research is needed to enhance ciliary function, address genetic diversity, and refine differentiation techniques for clinical use.